NYU Langone and NYU Grossman in the News
Inside the new NYU Langone CEO’s plans for growth
Modern Healthcare
In a Q&A with Modern Healthcare, NYU Langone Health Dean and CEO Alec C. Kimmelman, MD, PhD, discusses the system's growth strategy, highlighting several major new outpatient facilities it is opening in New York and Florida as well as plans for a state-of-the-art medical center in Melville on Long Island. He also discusses NYU Langone’s commitment to supporting patients from all backgrounds, noting the system’s $3.7 billion community benefit contributions in fiscal year 2025, as well as its commitment to using AI to further improve the patient experience and outcomes.
10/27/2026
New breakthrough in fight against devastating disease that kills 90K a year
New York Post
A landmark international study led by researchers from NYU Langone Health and its Perlmutter Cancer Center found that sacituzumab tirumotecan (sac-TMT) could become a new standard treatment for recurrent endometrial cancer. The phase 3 trial showed patients treated with sac-TMT had a 41% lower risk of cancer progression and a 32% lower risk of death compared to standard chemotherapy. According to study principal investigator Bhavana Pothuri, MD, gynecologic oncologist, professor in the Department of Obstetrics and Gynecology at NYU Grossman School of Medicine, and medical director of the Clinical Trials Office at Perlmutter Cancer Center, and co-investigator Michelle D. Lightfoot, MD, MPH, an assistant professor at NYU Grossman School of Medicine and gynecologic oncologist at Perlmutter Cancer Center, the findings offer hope.
10/26/2026
New York Post
The FDA has approved Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic adenocarcinoma. Clinical trials showed the treatment slowed disease progression and extended median overall survival to 13.2 months compared to 6.7 months with chemotherapy. Paul E. Oberstein, MD, service chief of the Gastrointestinal Medical Oncology Program and assistant director of the Pancreatic Cancer Center at NYU Langone’s Perlmutter Cancer Center, said the results are a major advance for a cancer that has historically had few effective treatment options. Researchers are hopeful this will lead to additional therapies.
Also reporting was: MSN
10/26/2026
Is it safe to be on a GLP-1 while pregnant?
CBS Mornings
Rachel Pessah-Pollack, MD, endocrinologist and clinical professor of medicine at NYU Langone Health, discusses new ACOG guidance on GLP-1 weight-loss drugs during pregnancy and breastfeeding. Because 40% of pregnancies are unintentional, experts recommend stopping GLP-1s one to two months before conception, as they lack proven safety and risk causing nutritional deficiencies or poor fetal growth. Regarding breastfeeding, guidelines suggest considering restarting after 28 days only in specific cases, like type 2 diabetes, though data remains sparse. Finally, Dr. Pessah-Pollack highlights that because GLP-1s can enhance fertility, healthcare providers strongly advise women using the medications to stay on reliable contraception before pregnancy.
10/26/2026
Should you try HRT for menopause symptoms? Long Island doctors weigh in *
Newsday
Following updated federal recommendations and the removal of a key FDA warning, menopause hormone therapy is seeing a resurgence. Long Island doctors discuss the treatment's history and benefits. Erika Banks, MD, chair of the Department of Obstetrics and Gynecology at NYU Langone Hospital—Long Island, notes that a flawed 2002 study made providers hesitant to prescribe it. Ilene Gewirtz, MD, a gynecologist and menopause specialist at NYU Langone Health, states that every patient requires individualized care. The article also includes perspectives from Northwell Health and Stony Brook Medicine.
10/27/2026
Patient safety requires practical, community-informed solutions
Forbes
The Elevance Health Foundation awarded $4 million through its inaugural Patient Safety Prize, which recognizes practical, community-informed solutions to improve patient safety. Among the recipients was NYU Grossman School of Medicine for its SAFER-Med program. SAFER-Med is an AI-powered, multilingual system that verifies medication understanding to prevent avoidable harm for heart failure patients transitioning home. Other organizations recognized include Care Synergy for its fall-prevention program, the Population Health Innovation Lab for cardiac health literacy, and Parkland Center for Clinical Innovation for an AI model predicting medication risks.
10/26/2026
New blood test can find one of the deadliest cancers returning—before scans
Newsweek
Researchers from NYU Langone Health and NYU Grossman School of Medicine have developed a new blood test that may detect the recurrence of non-small-cell lung cancer before it is visible on scans. The study found the liquid biopsy accurately predicted relapse risk with 75 percent sensitivity and a median lead time of 16.7 months. According to researcher Matija Snuderl, MD, director of molecular pathology and professor of pathology at NYU Langone Health, the new approach could improve follow-up care after surgery. Further prospective studies are needed before it can guide routine clinical decisions.
Also reporting was: Yahoo Health
10/26/2026
Never eat this 1 thing while taking antibiotics, researchers warn
Inc.
A multi-institution study from researchers at NYU Langone Health, City of Hope, and Memorial Sloan Kettering found that consuming sugar while taking antibiotics worsens gut microbiome damage. The research showed sugar intake was linked to a larger decline in microbiome diversity and blooms of harmful bacteria like Enterococcus faecium. Co-senior author Jonas Schluter, PhD, assistant professor in the Department of Microbiology at NYU Langone, noted that reducing sweets could help limit these risks. William Jogia, a PhD student in the Institute for Systems Genetics at NYU Grossman School of Medicine, also commented.
10/26/2026
Becker's ASC Review
An article lists 10 leaders in gastroenterology (GI) amid industry pressures like reduced payer reimbursement. Among the recognized academic leaders is Aasma Shaukat, MD, MPH, the Robert M. and Mary H. Glickman Professor of Medicine in NYU Langone's Department of Medicine and director of outcomes research in the Division of Gastroenterology and Hepatology at NYU Grossman School of Medicine. She is noted for her work on colorectal cancer screening quality, advanced polyp removal, and using AI to improve colonoscopy accuracy. The list also includes executives from major GI groups and professional societies.
10/26/2026
Incyte highlights promising early data for ’890 and ’734 in GI cancers
MarketBeat
Incyte presented updated clinical data for two experimental drugs targeting gastrointestinal cancers. Manuel Hidalgo Medina, MD, co-director of the Gastrointestinal Cancer Center at NYU Langone Health, presented Phase I data for the drug ’734. In advanced pancreatic cancer, ’734 combined with chemotherapy demonstrated high overall response rates. Hidalgo noted that several complete responses were observed, which is unusual for this disease. Incyte is now advancing the drug into pivotal studies based on these promising results.
Also reporting was: Yahoo Finance, MarketBeat, American Banking and Market News
10/26/2026
Need to get off the toilet fast? GI doctors say these diarrhea remedies can help
Aol
This article discusses common causes of diarrhea, such as bacteria, viruses, and food sensitivities. Most cases resolve on their own, according to expert Toyia James-Stevenson, MD, from IU Health. The piece identifies Rabia A. De Latour, MD, associate professor in the Department of Medicine at NYU Grossman School of Medicine, as a subject matter expert. It provides a list of effective home remedies and also outlines when it is necessary to seek professional medical attention, such as if there is blood in the stool, sleep disruption, or rapid weight loss.
10/26/2026
Global study reports rise in chronic kidney disease
Mercola.com
Researchers from NYU Langone Health, the University of Glasgow, and the University of Washington conducted a systematic analysis on chronic kidney disease (CKD), published in The Lancet. The study found that CKD prevalence more than doubled over three decades, rising from 378 million cases in 1990 to an estimated 788 million in 2023. According to the findings, CKD is now the ninth leading global cause of death, up from 17th in 1990, and accounted for an estimated 1.48 million deaths in 2023. High blood sugar, high blood pressure, and high BMI were identified as the main risk factors.
10/27/2026
Cardiologists grapple with AI-generated content in slides
TCTMD
Cardiologists are expressing concerns over the increasing use of artificial intelligence to create presentation slides for medical conferences, citing issues like inaccuracies and a lack of originality. Sripal Bangalore, MD, interventional cardiologist at NYU Langone Health, commented on experiencing 'AI fatigue,' noting many presentations look identical and lack a human touch. Experts from Mount Sinai and NewYork-Presbyterian also voiced concerns, stating that over-reliance on AI tools removes critical thinking from scientific dialogue and can damage a presenter's integrity by outsourcing the art of storytelling.
10/26/2026
Feeling nervous? Work that system to calm it down
Science News Explores
The article discusses methods for calming the body's stress response by activating the parasympathetic nervous system. While the sympathetic nervous system governs the 'fight-or-flight' mode, techniques like slow breathing, humming, and cold therapy can stimulate the vagus nerve to induce relaxation. These practices can help lower stress hormone levels, slow the heart rate, and reduce blood pressure. Patricio Millar Vernetti, MD, neurologist at NYU Langone Health, explains that while one cannot consciously slow the heart, these interventions provide more control over the body's physiological stress reactions.
10/26/2026
